Loading company
NewAmsterdam Pharma Co N.V.
NAMS · Nasdaq · ·
Next earnings: November 4, 2026
$23.82+1.0%Sep 29 close
- 1M
- -4.4%
- 6M
- -27.4%
- 1Y
- -18.9%
- 5Y
- +141.8%
NAMS · Nasdaq · ·
Next earnings: November 4, 2026
$23.82+1.0%Sep 29 close
NewAmsterdam Pharma Co N.V. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $3.7M | $19.1M | -80.67% |
| Profit | -$64.1M | -$17.4M | -269.36% |
| Profit per share | -$0.52 | -$0.15 | -246.67% |
| Free Cash Flow | -$39.3M | -$37.8M | -4.07% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“During the second quarter, we continued to build momentum across our regulatory, clinical, and scientific priorities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from NewAmsterdam Pharma Co N.V.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
NewAmsterdam Pharma Co N.V. has no earnings call transcript available.